CRF Connect Logo

Structural

Aortic Valve Disease

Clinical Trials & Science

Rationale and Status of “At Risk” Moderate AS Trials (PROGRESS and EXPAND TAVR II)

Original Broadcast: June 25, 2025

Conference: NY Valves 2025

Lecturer: Raj Makkar